Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study

被引：0
|
作者：
Israelyan, E. R. [1 ]
Tryakin, A. [2 ]
Rumyantsev, A. [1 ]
Fedyanin, M. [3 ]
Tyulyandina, A. [1 ]
Klimov, A. [4 ]
Matveev, V. [5 ]
Volkova, M. I. [6 ]
Paychadze, A. [7 ]
Bychkov, Y. [8 ,9 ]
Yunaev, G. [10 ]
Tsareva, A. [1 ]
Tikhomirova, T. [1 ]
Zorinova, A. [1 ]
Tjulandin, S. [11 ]
机构：
[1] Natl Med Res Ctr Oncol, Chemotherapy Dept 4, Moscow, Russia
[2] Natl Med Res Ctr Oncol, Clin Pharmacol & Chemotherapy Dept, Moscow, Russia
[3] Moscow Dept Hlth, Chemotherapy Dept, Moscow Multidisciplinary Clin Ctr Kommunarka, Moscow, Russia
[4] Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[5] NN Blokhin Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[6] City Clin Hosp, Moscow Healthcare Dept, Genitourinary Oncol Dept, Oncol Ctr 1, Moscow, Russia
[7] PA Hertsen Moscow Oncol Res Inst, Chemotherapy Dept, Moscow, Russia
[8] Russian Ctr Rentgenoradiol, Chemotherapy Dept, Moscow, Russia
[9] Moscow Res Inst Diagnost & Surg, Chemotherapy Dept, Moscow, Russia
[10] Natl Med Res Ctr Oncol, Intens Care Dept, Moscow, Russia
[11] Natl Med Res Ctr Oncol, Chemotherapy Dept 22, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.770
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页码：S543 / S543
页数：1
相关论文
共 50 条
  • [41] SURGICAL RESECTION IN PATIENTS WITH NONSEMINOMATOUS GERM-CELL TUMOR WHO FAIL TO NORMALIZE SERUM TUMOR-MARKERS AFTER CHEMOTHERAPY - EDITORIAL COMMENT
    DONOHUE, JP
    UROLOGY, 1994, 43 (01) : 80 - 80
  • [42] Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): Final results
    Sadeghi, Sarmad
    Quinn, David I.
    Tsao-Wei, Denice D.
    Hamid, Omid
    Hu, James
    Schuckman, Anne K.
    Daneshmand, Siamak
    Groshen, Susan G.
    Raghavan, Derek
    Dorff, Tanya B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James S.
    Patil, Sujata
    Reuter, Victor E.
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Milowsky, Matthew I.
    Appleman, Leonard Joseph
    Dorff, Tanya B.
    Bromberg, Maria
    Joseph, Gabriella
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Paclitaxel, Bleomycin, Etoposide, and Cisplatin (T-BEP) as initial treatment in patients. with poor-prognosis germ cell tumors (GCT):: A phase II study.
    Mardiak, J.
    Salek, T.
    Sycova-Mila, Z.
    Obertova, J.
    Reckova, M.
    Mego, M.
    Hlavata, Z.
    Brozmanova, K.
    Risnyovzska, Z.
    Svetlovska, D.
    Koza, I.
    NEOPLASMA, 2007, 54 (03) : 240 - 245
  • [45] Sequential dose-intensive paclitaxel plus ifosfamide and carboplatin plus etoposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts).
    Kondagunta, GV
    Bacik, J
    Bajorin, DF
    Reich, L
    Sheinfeld, J
    Bains, M
    Bosl, GJ
    Motzer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 378S - 378S
  • [46] Major prognostic value of modeled AUChCG-AFP, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG
    Boyle, H.
    You, B.
    Fronton, L.
    Ribba, B.
    Girard, P.
    Tranchand, B.
    Tod, M.
    Coquelin, H.
    Droz, J.
    Flechon, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Outcome following resection for patients with primary mediastinal nonseminomatous germ cell tumors and rising serum tumor markers post-chemotherapy
    Radaideh, S. M.
    Cook, V.
    Kesler, K. A.
    Einhorn, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] SURGICAL RESECTION OF SOLITARY METASTASES AFTER CHEMOTHERAPY IN PATIENTS WITH NONSEMINOMATOUS GERM-CELL TUMORS AND ELEVATED SERUM TUMOR-MARKERS
    WOOD, DP
    HERR, HW
    MOTZER, RJ
    REUTER, V
    SOGANI, PC
    MORSE, MJ
    BOSL, GJ
    CANCER, 1992, 70 (09) : 2354 - 2357
  • [49] A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis
    Patel, SR
    Papadopolous, N
    Raymond, AK
    Donato, M
    Seong, CM
    Yasko, AW
    Lewis, VO
    Lin, PP
    Champlin, R
    Benjamin, RS
    CANCER, 2004, 101 (01) : 156 - 163
  • [50] Clinical outcome and postoperative chemotherapy requirement in patients with clinical stage IIA and IIB non-seminomatous germ cell tumor (NSGCT) following primary retroperitoneal lymph node dissection: Impact of preoperative serum tumor markers (STM)
    Sheinfeld, J
    Stephenson, AJ
    Motzer, RJ
    Bajorin, DF
    Bosl, GJ
    JOURNAL OF UROLOGY, 2004, 171 (04): : 247 - 247
12345